CpG 7909 is a TLR9 ligand whose efficacy has been studied in the treatment of cutaneous T-cell lymphoma and NHL and in second-line therapy for patients with chronic lymphocytic leukemia [176]. This evidence concerns the gene TLR9 and non-Hodgkin lymphoma.